Key Facts and Data Points

  • CAR T‑cell therapy: A personalized cancer immunotherapy where a patient’s T‑cells are engineered to express Chimeric Antigen Receptors (CARs).
  • NexCAR19: India’s first indigenous CAR‑T product, approved in 2023; developed by IIT Bombay, Tata Memorial Centre, and ImmunoACT.
  • Current global cost: Rs 3‑4 crore per treatment course.
  • Study finding: Replacing harsh enzymes (Trypsin/TrypLE) with Accutase for cell recovery from 3‑D scaffolds yields higher cell viability and preserved immune function.
  • Potential impact: Reducing cell loss can bring the cost of Indian CAR‑T therapies to a fraction of the global price.

Background and Context

  • T‑cells are white‑blood cells that identify and eliminate infected or malignant cells.
  • CAR T‑cell therapy involves:
  1. Harvesting patient’s T‑cells.
  2. Genetically inserting a CAR gene.
  3. Expanding the modified cells in vitro.
  4. Infusing them back into the patient.
  • The technology is currently approved for certain hematological malignancies (e.g., acute lymphoblastic leukaemia, diffuse large B‑cell lymphoma).
  • Manufacturing challenges include efficient cell expansion and gentle recovery from 3‑D culture systems.

Significance for India / Governance / Policy

  • Cost reduction: By improving cell recovery, India can lower the per‑patient cost, making CAR‑T therapy accessible to a larger population.
  • Indigenous innovation: Success of NexCAR19 and the Accutase protocol showcases India’s shift from generic drug manufacturing to high‑end cell‑and‑gene therapy.
  • Strategic health security: Domestic capability reduces dependence on expensive imports and aligns with the ‘Make in India’ agenda for advanced biopharma.
  • Policy implications:
  • Need for strengthened regulatory pathways (CDSCO) for cell‑based products.
  • Funding incentives for biotech startups and academic‑industry collaborations.
  • Development of skilled workforce in cellular engineering and GMP‑grade manufacturing.

Related Constitutional / Legal Provisions

  • Article 47 of the Constitution (Directive Principles) emphasizes the duty of the State to improve public health.
  • The Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019 govern approval of advanced therapies like CAR‑T.
  • Intellectual Property Rights: Patents on CAR constructs are covered under the Patents Act, 1970, with provisions for compulsory licensing to ensure affordability.

Frequently Asked Questions (FAQs)

  1. What are T‑cells? – White‑blood cells central to adaptive immunity.
  2. Why is cell recovery important? – Damaged cells compromise therapeutic efficacy.
  3. What makes Accutase preferable? – It gently detaches cells without stripping surface proteins.
  4. Which cancers are currently treatable with CAR‑T? – Primarily blood cancers such as leukaemia and lymphoma.
  5. How does NexCAR19 position India globally? – As the producer of the world’s most affordable indigenous CAR‑T therapy.

Prepared for UPSC Civil Services Examination – Current Affairs & Science & Technology